Pre-stroke and post-stroke day3 locomotion measurements both confirmed that there was no significant difference on basal level locomotion measurement and psd 3 locomotion deficits between the two groups before the initiation of vehicle or SAG treatment (total distance traveled = 19630.4±1302.3cm for vehicle group and 20217.0±1386.4 cm for SAG treatment group, p = 0.97; total movement number = 5316.9±200.7 for vehicle group and 5478.9±235.8 for SAG treatment group, p = 0.88, Student’s t-test, Fig 7A and 7B). The gene discussed is PSD; the disease is Stroke.